Spruce Biosciences, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Spruce Biosciences, Inc. (SPRB) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $9.51 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-12
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $9.51M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $10.14M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.00K.
- 2025-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $9.51M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $10.14M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $7.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $11.00K 10-K · filed 2025-04-15 |
| 2024-09-30 | $17.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $23.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $31.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $39.00K 10-K · filed 2024-03-18 |
| 2023-09-30 | $49.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $60.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $72.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $85.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $99.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $112.00K 10-Q · filed 2022-08-10 |
| 2022-03-31 | $110.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $122.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $133.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $145.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $157.00K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $24.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $31.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |